Cameron Turtle, DPhil
Chief Operating Officer
Cameron Turtle, DPhil, is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Dr. Turtle joins Aeglea from Spyre Therapeutics. Previously, he served as Venture Partner at Foresite Labs; Chief Strategy Officer of BridgeBio Pharma (NASDAQ: BBIO); and Chief Business Officer of Eidos Therapeutics (NASDAQ: EIDX), where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A and due diligence, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his DPhil in Cardiovascular Medicine from the University of Oxford, St. John’s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award.
Chief Financial Officer
Scott Burrows is the Chief Financial Officer of Aeglea BioTherapeutics. He has proven expertise in biopharmaceutical finance, having worked in finance leadership roles for several public companies across two decades. Before joining Aeglea, he served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. ("Arcutis") (Nasdaq: ARQT), where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial-stage company. Prior to Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc based in Switzerland. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant. He earned his BA and MBA from the University of California, Los Angeles, and is a licensed CPA (inactive).
Heidy Abreu King-Jones
Chief Legal Officer & Corporate Secretary
Heidy King-Jones is the Chief Legal Officer and Corporate Secretary for Aeglea BioTherapeutics. Previously, she served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc. and led the legal work and strategy for the company’s various financings, the approval of Tzield®, the successful transition from clinical-stage to commercial-stage, and its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc., where she was responsible for Axcella's corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc., including overseeing all Corporate Law matters as Senior Director, Corporate Law as well as the compliance and legal work for commercialization of Exondys51®. Ms. King-Jones began her legal career in the Securities & Public Companies Practice Group at Ropes & Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility and technology industries. She holds a J.D. and LL.M. in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College.
Russell J. Cox
Chief Executive Officer, Epirium Bio
Russell Cox is president, chief executive officer and a member of the board of directors of Epirium Bio. Russell also serves on the board of directors of Gossamer Bio. Previously, he served as chief executive officer and a member of the board of directors at Vital Therapies. He also formerly served as executive vice president and chief operating officer of Jazz Pharmaceuticals. As COO he held responsibility for the company’s Commercial, R&D, Manufacturing, International, and Global Molecule Leadership teams. He worked in a variety of escalating senior management roles from 2010 to 2018, including executive vice president and chief commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was senior vice president and chief commercial officer of Ipsen Group, and from 2007 until December 2008 he was vice president of marketing at Tercica, Inc., a biotechnology company acquired by Ipsen Group. From 2003 to 2007, he was with Scios, Inc. (acquired by Johnson & Johnson in 2003), where he served as vice president of marketing. Prior to 2003, Russell was with Genentech, Inc. for 12 years, where he was a product team leader responsible for the company’s growth hormone franchise and led numerous product launches as a group product manager. Russell received a B.S. in biomedical science from Texas A&M University.
Managing Member, Fairmount Funds
Peter Harwin is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of Cogent Biosciences, Inc. and is a director of Paragon Therapeutics, Inc., and Apogee Therapeutics, LLC. Peter holds a Bachelor of Business Administration from Emory University.
Chief Executive Officer of Apogee Therapeutics
Michael Henderson, M.D., is the CEO of Apogee Therapeutics, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. He is a proven biotechnology industry leader with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of more than 20 companies, launched 40 drug development programs, and led teams to two FDA approvals, to date. Michael received his B.A. from Harvard University and holds an M.D. from Stanford University.
Managing Member, Fairmount Funds
Tomas Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC. In addition to Viridian, Mr. Kiselak serves as a director for several private companies. He received a bachelor’s degree in Neuroscience and Economics from Amherst College.
Former President and CEO of Kaleido Biosciences
Alison Lawton is an executive leader with more than 30 years of experience in biopharma and most recently served as president and CEO of Kaleido Biosciences. Prior to Kaleido Biosciences, she served as chief operating officer of Aura Biosciences and OvaScience and worked at various positions of increasing responsibility at Genzyme, and subsequently at Sanofi-Aventis, including as head of Genzyme Biosurgery and prior senior vice president of Global Market Access. Alison currently serves as independent director for X4 Pharmaceuticals and ProQR Therapeutics and has served on the boards of directors of Verastem, CoLucid until its acquisition by Eli Lilly, and Cubist Pharmaceuticals until its acquisition by Merck & Co. She is past president and chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee. She earned her BSc in Pharmacology, with honors, from King’s College London.
Ivana Magovčević-Liebisch, Ph.D., J.D.
President & Chief Executive Officer, Vigil Neuroscience
Dr. Ivana Magovčević-Liebisch has 20 years of senior management experience in biopharma with expertise in corporate development, M&A, IP and legal strategy, and pipeline and product portfolio development. She is currently the president and chief executive officer of Vigil Neuroscience. Prior to Vigil Neuroscience, she was executive vice president, chief business officer of Ipsen, a biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases. Ivana previously served as the executive vice president, chief strategy and corporate development officer of Axcella Health Inc. From 2013 to 2017, she was senior vice president and head of global business development at Teva Pharmaceutical Industries, where she spearheaded multiple transactions ranging from licensing to acquisitions for the specialty drug business. From 2001 to 2013, she worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. From 1998 to 2001, she was patent counsel and director of intellectual property at Transkaryotic Therapies. Ivana has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. in High Technology law from Suffolk University Law School.
Hunter C. Smith, M.B.A.
Chief Financial Officer, Rhythm Pharmaceuticals
Hunter Smith has served as the chief financial officer and treasurer of Rhythm Pharmaceuticals since 2017 and served as interim chief executive officer from March to July 2020. Prior to joining Rhythm, Hunter was vice president, finance and chief financial officer of Celgene Corporation’s inflammation and immunology business unit where he provided financial and strategic leadership for the global launch of Otezla®. Prior to Celgene, he held roles of increasing responsibility at Bunge Limited,a global food and agribusiness company, including director of investor relations, chief financial officer—Asia, corporate treasurer, and chief financial officer of Bunge's sugar and bioenergy segment. Hunter holds an M.B.A in finance from NYU’s Stern School of Business and a B.A. in history, with honors, from Northwestern University.